Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 12, 2012, Pages 2912-2918

  Reynolds, R ^a,h   Hope, R ^b   Warner, M ^b   MacGowan, A P ^j   Livermore, D M ^b,c,g   Ellington, M J ^d   Allen, M ^j   Brown, D ^j   Grundmann, H ^e   Heginbothom, M ^j   Kidney, A ^f   Martin, V ^h   Morrissey, I ^f   Mushtaq, S ⁱ   Pick, C ^j   Porter, J ^j   Shah, A ^j   Steenbergen, J ^j   Thomson, C ^j   White, A ^j  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^f Department of Microbiology   (United Kingdom)

^g UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^h NORTH BRISTOL NHS TRUST   (United Kingdom)

ⁱ HPA   (United Kingdom)

^j NONE

more..

Author keywords

Antimicrobial resistance surveillance; Bacteraemia; MIC creep; S. aureus; Teicoplanin; Vancomycin

Indexed keywords

GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; IRELAND; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; UNITED KINGDOM;

EID: 84869472086     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks324     Document Type: Article

References (18)

1. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 2.0, Valid From 2012-01-01. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf (2 August 2012, date last accessed).
2. EUCAST. Antimicrobial Wild Type Distributions of Microorganisms- Staphylococcus aureus. http://217.70.33.99/Eucast2/SearchController/search.jsp?action=&BeginIndex=50&Micdif=mic&NumberIndex=50&Antib=-1&Specium=14 (2 August 2012, date last accessed).
3. Ho P-L, Lo P-Y, Chow K-H et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infection 2010; 60: 140-5.
4. Kehrmann J, Kaase M, Szabados F et al. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur J Microbiol Infect Dis 2011; 30: 677-83.
5. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 2006; 57: 506-10.
6. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in nonvancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60: 788-94.
7. Wang G, Hindler JF, Ward KW et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883-6.
8. EUCAST. Vancomycin, Rationale for the EUCAST Clinical Breakpoints, Version 2.1. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Vancomycin_rationale_2.1.pdf (2 August 2012, date last accessed).
9. Hope R, Livermore DM, Brick G et al. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001 to 2006. J Antimicrob Chemother 2008; 62 Suppl 2: ii65-74.
10. Reynolds R, Hope R, Williams L et al. Survey, laboratory, and statistical methods for the BSAC Resistance Surveillance Programmes. J Antimicrob Chemother 2008; 62 Suppl 2: ii15-28.
11. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48 Suppl S1: 5-16.
12. BSAC Working Party on Susceptibility Testing. BSAC Methods for Antimicrobial Susceptibility Testing, Version 11 March 2012. http://bsac.org.uk/wp-content/uploads/2012/02/Version-11-2012-Final.pdf (2 August 2012, date last accessed).
13. Ellington MJ, Hope R, Livermore DM et al. Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007. J Antimicrob Chemother 2010; 65: 446-8.
14. Edwards B, Milne K, Lawes T et al. Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol 2012; 50: 318-25.
15. Hawser SP, Bouchillon SK, Hoban DJ et al. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents 2011; 37: 219-24.
16. Zhanel GG, Adam HJ, Low DE et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-9 study. Diagn Microbiol Infect Dis 2011; 69: 291-306.
17. Adam HJ, Louie L, Watt C et al. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob Agents Chemother 2010; 54: 945-9.
18. Sader HS, Fey PD, Fish DN et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009; 53: 4127-32.